Randomized Controlled Trial
Copyright ©The Author(s) 2021.
World J Diabetes. Mar 15, 2021; 12(3): 292-305
Published online Mar 15, 2021. doi: 10.4239/wjd.v12.i3.292
Table 2 Comparison of baseline characteristics of the intervention and control groups at baseline, 2 mo, 6 mo, and 12 mo
VariableBaseline
2 mo
6 mo
12 mo
CBTControlχ2/t valueP valueCBTControlχ2/t valueP valueCBTControlχ2/t valueP valueCBTControlχ2/t valueP value
Participant number568574------550559541549------506527------
Gender (female)
Female3703830.320.573623760.260.613563700.310.583353671.400.24
Age (mean + SD)61.58 ± 9.1761.83 ± 8.64-0.460.6561.75 ± 9.1262.10 ± 8.86-0.640.5262.48 ± 9.1462.75 ± 8.71-0.500.6262.87 ± 9.2562.74 ± 8.870.230.82
Educational level
High school and above53560.420.8151560.380.8347561.090.5841501.000.61
Junior high school240251234243231240208223
High school and above275267265260263253257254
Hypertension2872870.030.862762780.020.882702720.010.912522620.000.98
Comorbidities1091180.340.561091140.060.811071100.010.92911101.370.24
BMI24.77± 4.1525.20± 4.94-1.600.1124.99 ± 4.4825.00 ± 4.94-0.060.9624.71 ± 4.0925.22 ± 5.01-1.840.0724.76 ± 4.0025.28 ± 5.02-1.840.07
Drinking55660.990.3255650.760.3854640.790.3746490.010.91
Smoking80920.840.3679880.410.5276860.560.4564690.050.83
Course of the disease (yr)5.07 ± 5.255.21 ± 4.910.560.645.20 ± 5.065.41 ± 5.36-0.660.515.53 ± 5.215.66 ± 4.76-0.430.676.03 ± 5.286.20 ± 4.68-0.520.60
Medication
Oral hypoglycemic agents4914831.560.464764701.760.424724651.720.424484445.960.05
Insulin4549424639443743
Oral hypoglycemic agents plus insulin3242324330402140
GAD-7 score7.56 ± 5.207.58 ± 5.25-0.040.977.47 ± 5.237.22 ± 5.480.760.457.53 ± 5.657.14 ± 5.931.100.277.14 ± 5.686.34 ± 5.562.270.02
PHQ-9 score7.13 ± 5.536.94 ± 5.470.590.557.23 ± 5.367.00 ± 5.020.730.467.21 ± 5.486.74 ± 5.211.440.157.20 ± 5.456.10 ± 4.973.390.00